IBRX ImmunityBio, Inc.

ImmunityBio, Inc. and NantKwest, Inc. merged on March 9, 2021 to create a leading late-stage, cell therapy and immunotherapy company focused on oncology and infectious diseases. The combined company is called ImmunityBio, Inc.

$10.00  -0.67 (-6.28%)
As of 09/28/2021 15:59:55 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Mid cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  03/10/2021
Outstanding shares:  391,156,513
Average volume:  1,088,392
Market cap:   $3,876,361,044
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    45256X103
ISIN:        US45256X1037
Sedol:      BNSP0B8
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   0.00
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy